Polizzi C A, Carelli M, Giampaolo P, Di Marcotullio G, Tubaro M, Malinconico U, Milazzotto F
Clin Ter. 1989 Feb 15;128(3):183-9.
Flecainide (F) is a new antiarrhythmic agent recently introduced into clinical practice. The above study was aimed at evaluating its intravenous (iv) pharmacokinetics in patients (pts) with acute myocardial infarction (AMI) on 1st and 2nd day, complicated by complex ventricular premature beats (VPBs). 2 mg/kg F was given iv as bolus injection, followed by 300 mg/24 hrs iv infusion. Plasma F values were evaluated by HPLC. Plasma F levels increased progressively, in a non uniform but predictable manner: in pts with large AMI and cardiac failure, F plasma levels, although remaining within the therapeutic range, were greatly increased after the 2nd hour (P less than 0.05) in comparison with pts without cardiac insufficiency. Negative side effects, both cardiac and extracardiac, were not observed: F appeared a handy and effective agent in post-AMI arrhythmias, especially when plasma drug levels are controlled; plasma F level monitoring is anyway recommended in pts with cardiac failure, owing to the wide interindividual variations.
氟卡尼（F）是一种最近引入临床实践的新型抗心律失常药物。上述研究旨在评估其在急性心肌梗死（AMI）第1天和第2天并发复杂室性早搏（VPB）患者中的静脉（iv）药代动力学。以2mg/kg的剂量静脉推注氟卡尼，随后以300mg/24小时的速度静脉输注。通过高效液相色谱法（HPLC）评估血浆氟卡尼值。血浆氟卡尼水平呈逐渐升高趋势，方式不均匀但可预测：在大面积AMI和心力衰竭患者中，与无心脏功能不全的患者相比，第2小时后血浆氟卡尼水平虽仍在治疗范围内，但大幅升高（P<0.05）。未观察到心脏和心脏外的负面副作用：氟卡尼在AMI后心律失常中似乎是一种方便有效的药物，尤其是在血浆药物水平得到控制时；无论如何，由于个体差异较大，建议对心力衰竭患者进行血浆氟卡尼水平监测。
